Clozapine and the Mandatory Monitoring System

L. S. Lehmann, L. Rodriguez, Joseph H. Friedman, Carol A. Bernstein, Robert Eilers

Research output: Contribution to journalLetter

3 Citations (Scopus)

Abstract

To the Editor: Dr. Salzman, in his Sounding Board article (Sept. 20 issue),1 has identified key aspects of what he generously characterizes as an “unusual” marketing strategy employed by Sandoz in tying the availability of the new antipsychotic agent clozapine (Clozaril) to its own monitoring and distribution system (the Clozaril Patient Monitoring System, or CPMS). This logistically cumbersome system accounts for some $7,000 of the exorbitant $9,000 annual cost per patient for Clozaril. The Department of Veterans Affairs (VA) has developed an alternative monitoring system with an automatic computerized lockout feature that prevents the dispensing of clozapine to a patient.

Original languageEnglish (US)
Pages (from-to)490-491
Number of pages2
JournalNew England Journal of Medicine
Volume324
Issue number7
DOIs
StatePublished - Feb 14 1991
Externally publishedYes

Fingerprint

Clozapine
Physiologic Monitoring
Veterans
Marketing
Antipsychotic Agents
Costs and Cost Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clozapine and the Mandatory Monitoring System. / Lehmann, L. S.; Rodriguez, L.; Friedman, Joseph H.; Bernstein, Carol A.; Eilers, Robert.

In: New England Journal of Medicine, Vol. 324, No. 7, 14.02.1991, p. 490-491.

Research output: Contribution to journalLetter

Lehmann, LS, Rodriguez, L, Friedman, JH, Bernstein, CA & Eilers, R 1991, 'Clozapine and the Mandatory Monitoring System', New England Journal of Medicine, vol. 324, no. 7, pp. 490-491. https://doi.org/10.1056/NEJM199102143240712
Lehmann, L. S. ; Rodriguez, L. ; Friedman, Joseph H. ; Bernstein, Carol A. ; Eilers, Robert. / Clozapine and the Mandatory Monitoring System. In: New England Journal of Medicine. 1991 ; Vol. 324, No. 7. pp. 490-491.
@article{7d39cbe1de5d4dc09141afc6f92b8b3d,
title = "Clozapine and the Mandatory Monitoring System",
abstract = "To the Editor: Dr. Salzman, in his Sounding Board article (Sept. 20 issue),1 has identified key aspects of what he generously characterizes as an “unusual” marketing strategy employed by Sandoz in tying the availability of the new antipsychotic agent clozapine (Clozaril) to its own monitoring and distribution system (the Clozaril Patient Monitoring System, or CPMS). This logistically cumbersome system accounts for some $7,000 of the exorbitant $9,000 annual cost per patient for Clozaril. The Department of Veterans Affairs (VA) has developed an alternative monitoring system with an automatic computerized lockout feature that prevents the dispensing of clozapine to a patient.",
author = "Lehmann, {L. S.} and L. Rodriguez and Friedman, {Joseph H.} and Bernstein, {Carol A.} and Robert Eilers",
year = "1991",
month = "2",
day = "14",
doi = "10.1056/NEJM199102143240712",
language = "English (US)",
volume = "324",
pages = "490--491",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "7",

}

TY - JOUR

T1 - Clozapine and the Mandatory Monitoring System

AU - Lehmann, L. S.

AU - Rodriguez, L.

AU - Friedman, Joseph H.

AU - Bernstein, Carol A.

AU - Eilers, Robert

PY - 1991/2/14

Y1 - 1991/2/14

N2 - To the Editor: Dr. Salzman, in his Sounding Board article (Sept. 20 issue),1 has identified key aspects of what he generously characterizes as an “unusual” marketing strategy employed by Sandoz in tying the availability of the new antipsychotic agent clozapine (Clozaril) to its own monitoring and distribution system (the Clozaril Patient Monitoring System, or CPMS). This logistically cumbersome system accounts for some $7,000 of the exorbitant $9,000 annual cost per patient for Clozaril. The Department of Veterans Affairs (VA) has developed an alternative monitoring system with an automatic computerized lockout feature that prevents the dispensing of clozapine to a patient.

AB - To the Editor: Dr. Salzman, in his Sounding Board article (Sept. 20 issue),1 has identified key aspects of what he generously characterizes as an “unusual” marketing strategy employed by Sandoz in tying the availability of the new antipsychotic agent clozapine (Clozaril) to its own monitoring and distribution system (the Clozaril Patient Monitoring System, or CPMS). This logistically cumbersome system accounts for some $7,000 of the exorbitant $9,000 annual cost per patient for Clozaril. The Department of Veterans Affairs (VA) has developed an alternative monitoring system with an automatic computerized lockout feature that prevents the dispensing of clozapine to a patient.

UR - http://www.scopus.com/inward/record.url?scp=0025979721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025979721&partnerID=8YFLogxK

U2 - 10.1056/NEJM199102143240712

DO - 10.1056/NEJM199102143240712

M3 - Letter

C2 - 1988837

AN - SCOPUS:0025979721

VL - 324

SP - 490

EP - 491

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 7

ER -